Vertigo Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Vertigo Drugs Market Size 2024-2028

The vertigo drugs market size is forecast to increase by USD 561.8 million at a CAGR of 5.44% between 2023 and 2028.

• The market is experiencing significant growth due to several key factors. One of the primary drivers is the increasing demand for vertigo medications in emerging economies, as the prevalence of vestibular disorders and imbalance issues continues to rise. Another trend shaping the market is the integration of digital health solutions in the treatment of vertigo, enabling remote monitoring and teleconsultation services. Additionally, the availability of affordable generic drugs for vertigo is providing increased accessibility to patients, particularly in regions with limited healthcare resources. These factors are expected to fuel market growth and create opportunities for market participants in the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

• The market is witnessing significant growth due to the increasing incidence and prevalence of vestibular disorders among the geriatric population. With the ongoing healthcare expenditure trends and the shift towards outpatient care, the demand for effective vertigo treatments is on the rise. The social distancing measures implemented due to the pandemic have further accelerated this trend, as patients prefer to avoid hospital visits for non-emergency conditions. Peripheral vertigo, including benign paroxysmal positional vertigo (BPPV) and Meniere's disease, are common vestibular disorders that cause dizziness and imbalance. These conditions affect the vestibular labyrinth and the vestibular nerve, leading to symptoms such as vertigo, tinnitus, and hearing loss.

• Clinical trials for new vertigo drugs are underway to address the unmet needs in this area. These new treatments aim to provide relief from symptoms and improve the quality of life for the elderly community. Medications such as corticosteroids, antibiotics, and vestibular suppressants are commonly used to manage vertigo. The route of administration for these drugs varies, with oral being the most common method. The healthcare services sector is responding to the growing demand for vertigo treatments by setting up specialized clinics, such as balance disorder clinics and ear, nose, and throat (ENT) clinics. Apollo Hospital, Neuroequilibrium, and Biomed Central are some of the notable institutions focusing on the diagnosis and treatment of vestibular disorders.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type
  • Peripheral vertigo
  • Central vertigo
• Distribution Channel
  • Offline
  • Online
• Geography
  • North America
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Type Insights

• The peripheral vertigo segment is estimated to grow significantly during the forecast period.

Peripheral vertigo, a type of dizziness or imbalance, results from issues in the inner ear's vestibular labyrinth or semicircular canals. These areas are responsible for maintaining balance. The problem may also involve the vestibular nerve, which connects the inner ear to the brain stem. Approximately 80% of vertigo cases are peripheral. Causes include injuries, certain medications such as aminoglycoside antibiotics and cisplatin, inner ear irritation and swelling, and conditions like Meniere's disease. The nystagmus, or unidirectional, fatigue-inducing horizontal or rotary eye movements, associated with peripheral vertigo worsen with head motions. Peripheral vertigo can lead to vestibular neuritis, typically a post-viral inflammatory syndrome.

Get a glance at the market report of share of various segments Request Free Sample

The peripheral vertigo segment was valued at USD 1.12 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 42% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

The North American region dominates the market due to its advanced healthcare services, large geriatric population, and significant healthcare expenditure. In 2023, North America accounted for the largest market share, driven by the presence of several leading pharmaceutical companies, including Viatris, Amneal Pharmaceuticals, and Epic Pharma. These companies invest in research and development to introduce innovative vertigo drugs with enhanced efficacy and safety profiles. The region's well-established pharmaceutical infrastructure and expertise enable the availability of a wide range of vertigo drugs, catering to the increasing demand from outpatients and patient visits. The incidence and prevalence of peripheral vertigo are high in the geriatric population, making North America an essential market for vertigo drugs. The region's focus on social distancing measures and digital health solutions further boosts the market growth.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in the adoption of Vertigo Drugs Market?

Rising demand for vertigo drugs in emerging economies is the key driver of the market.

• The market is experiencing significant growth due to the increasing demand for advanced healthcare services and medications in emerging economies. Countries such as India, China, Brazil, South Africa, Indonesia, Mexico, and others, characterized by rapid economic growth and increasing healthcare expenditure, are prioritizing the treatment of symptoms like dizziness, headaches, nausea, and vomiting associated with vertigo. This focus is aimed at improving patient outcomes and enhancing quality of life. The healthcare infrastructure in these regions is evolving, leading to an increased emphasis on vertigo drugs. Furthermore, there is a growing awareness of healthcare and improved accessibility to medical services, driving the demand for vertigo medications.

• The geriatric population, a significant demographic affected by vertigo, is also expanding in these regions, further fueling market growth. The market includes a range of medications such as corticosteroids, antibiotics, and vestibular suppressants, administered through various routes including oral and injectable. Companies specializing in vertigo treatments, like NeuroEquilibrium and Altamira Therapeutics, are conducting clinical trials for new medications and technologies, such as nasal sprays and wearable head sensors, to address the unmet needs of the elderly community. The financial burden of vertigo treatment, particularly for chronic conditions like benign paroxysmal positional vertigo, Meniere's Disease, and central vertigo, is a key consideration for patients and healthcare systems alike.

What are the market trends shaping the Vertigo Drugs Market?

Integration of digital health solutions in vertigo is the upcoming trend in the market.

• The market is witnessing significant growth due to the increasing healthcare expenditure and the rising incidence and prevalence of vertigo among the geriatric population. Vertigo, a common balance disorder, affects the vestibular system of the inner ear and results in dizziness, disequilibrium, and spatial disorientation. According to the National Institute on Deafness and Other Communication Disorders, about 69 million Americans experience some form of dizziness each year, with peripheral vertigo being the most common type. Benign paroxysmal positional vertigo (BPPV) and Meniere's Disease are two common conditions that cause vertigo. Clinical trials are ongoing to develop new medications and therapies to treat these conditions.

• Corticosteroids, antibiotics, vestibular suppressants, and generic drugs are among the commonly used medications for vertigo. The route of administration varies, with some medications available in oral and injectable forms, while others require homecare or specialty clinics. The integration of digital health solutions, such as telehealth platforms, in the field of vertigo is gaining momentum. These platforms offer innovative ways to track, monitor, and manage symptoms associated with vertigo, enabling timely interventions and reducing the need for unnecessary hospital visits. Healthcare infrastructure is also evolving to cater to the needs of the elderly community, with balance disorder clinics and specialized vestibular therapists becoming more common.

What challenges does Vertigo Drugs Market face during its growth?

The presence of generic drugs for vertigo is a key challenge affecting the market growth.

• The market in the healthcare services sector has been influenced by the increasing incidence and prevalence of balance disorders among the geriatric population. With the ongoing social distancing measures, there has been a shift towards outpatient care and patient visits to specialty clinics such as the Balance Disorder Clinic at Apollo Hospital and NeuroEquilibrium. The healthcare expenditure on vertigo treatments has risen due to the growing financial burden on patients, particularly those suffering from peripheral vertigo, benign paroxysmal positional vertigo, and Meniere's Disease. Clinical trials are ongoing for new medications like Betahistine from Altamira Therapeutics, which is being developed as a nasal spray under the brand name Vertigenius.

• Other treatments include vestibular suppressants administered through oral or injectable routes, corticosteroids, and antibiotics. Homecare solutions and wearable head sensors are also gaining popularity in the market. The presence of generic drugs in the market following patent expiration has led to increased competition and decreased sales for branded drugs. This trend is expected to continue, posing a threat to market players and disrupting market positions. The healthcare infrastructure in the US is investing in awareness initiatives to educate the elderly community about the importance of early diagnosis and treatment of vertigo. Benzodiazepines are also used in the treatment of vertigo, but their long-term use can lead to financial and health-related burdens for patients.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Altamira Therapeutics Ltd.: The company offers vertigo drugs such as ALTA-5206.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AdvaCare Pharma
• Altamira Therapeutics Ltd.
• Amneal Pharmaceuticals Inc.
• Endo International Plc
• Epic Pharma LLC
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Indicus Pharma
• Intas Pharmaceuticals Ltd.
• Jubilant Pharmova Ltd.
• Lupin Ltd.
• Novartis AG
• Otonomy Inc.
• Pfizer Inc.
• Sensorion
• Sound Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Suven Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

The market encompasses a range of medications and therapies designed to alleviate symptoms of vertigo, a common balance disorder characterized by the sensation of spinning or dizziness. Vertigo affects individuals across all age groups, but its prevalence is particularly high among the geriatric population. According to various studies, the incidence and prevalence of vertigo increase with age, making it a significant health concern for the elderly community. Healthcare expenditure on vertigo and its related conditions is substantial due to the high number of patient visits and the need for ongoing care.

Moreover, the outpatient setting is the primary venue for vertigo treatment, with specialty clinics and balance disorder clinics being the most common points of care. Hospitals also play a crucial role in managing severe cases and providing emergency care. The vestibular system, responsible for maintaining balance and spatial orientation, includes the vestibular labyrinth and the vestibular nerve. Peripheral vertigo, which results from issues in the inner ear or vestibular nerve, is the most common form of vertigo. Benign paroxysmal positional vertigo (BPPV) and Meniere's disease are two common conditions that contribute to peripheral vertigo. Clinical trials and research initiatives are ongoing to develop new treatments and improve existing ones.

Furthermore, medications, such as corticosteroids and antibiotics, are commonly used to treat vertigo. Corticosteroids help reduce inflammation, while antibiotics address any underlying bacterial infections. Vestibular suppressants are another class of medications used to manage vertigo symptoms. The route of administration for vertigo medications varies, with oral and injectable options available. Homecare solutions, such as generic drugs, offer cost-effective alternatives for patients. The patent expiration of key medications has led to increased competition in the market, driving down prices and expanding access to care. The patient epidemiology of vertigo highlights the need for awareness initiatives and targeted healthcare infrastructure development.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch